Clinical trials: Drug Safety, open to volunteers
Systemic Lupus Erythematosus, Rheumatoid Arthritis
A Study to Learn About a Medicine Called PF-08154225 in Participants With Autoimmune Diseases
The purpose of this study is to learn about the safety and effects of the study medication called PF-08154225 for the potential treatment of autoimmune diseases.
- Conditions
- Systemic Lupus Erythematosus, Rheumatoid Arthritis, Idiopathic Inflammatory Myositis, Systemic Sclerosis
- Trial name
- NCT07782450
- Testing
- PF-08154225
- Volunteers
- 54 people
- Sponsor
- Pfizer
Non-Small Cell Lung Cancer
A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations
This is a multicenter, randomized, open-label, controlled phase II clinical study to evaluate the efficacy and safety of HS-20093 injection combined with adebrelimab versus HS-20093 injection in previously treated patients with…
- Trial name
- NCT07824882
- Testing
- HS-20093 for Injection, Adebrelimab Injection
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Hansoh BioMedical R&D Company
Heart Failure With Reduced Ejection Fraction
Study Assessing Left Ventricular Administration of a Genetic Medicine Directing Organ Regeneration in Heart Failure
This clinical trial investigates the safety and preliminary effectiveness of YAP101, a gene therapy designed to improve heart function in adults with ischemic heart failure and reduced ejection fraction (HFrEF).
- Trial name
- SALVADOR-HF (NCT06831825)
- Testing
- YAP101 (AAV9-Sav-shRNA)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Medley Therapeutics
Healthy
A Study to Learn About the Medicine Called PF-08653944 in People With and Without Reduced Liver Function
This study is being done to learn more about an investigational medicine called PF-08653944. The goal is to understand how the body handles the medicine and to check its safety after a single dose.
- Trial name
- NCT07519135
- Testing
- PF-08653944
- Where
- 3 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Pfizer
Kidney Disease
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
Immunoglobulin A nephropathy (IgAN) is a kidney condition. It happens when the body's immune system creates groups of proteins (called immune complexes) that build-up in the kidneys causing swelling (inflammation).
- Trial name
- NCT06963827
- Testing
- Mezagitamab
- Where
- 186 sites in United States, Argentina and 24 more
- Volunteers
- 347 people
- Sponsor
- Takeda
HIV -1 Infection
Safety Study of MucoCept-CVN
MucoCept-CVN uses a Lactobacillus strain native to the human vagina that is modified into a live biotherapeutic product (LBP) that continuously expresses a potent anti-HIV drug.
- Trial name
- NCT07181486
- Testing
- Live Biotherapeutic Product L. jensenii 1153-1666
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Craig Cohen, MD, MPH
Smart Eyewear
Smart Eyewear to Automatically Detect Drug Delivery Events
This project is designed as a prospective observational study of medication preparation and delivery using a novel wearable data input device to automate detection of drug delivery events in the anesthesia workspace at University…
- Trial name
- NCT05184660
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Washington
Tardive Dyskinesia
Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia
The primary objective of this study is to evaluate the efficacy of NBI-1065890 compared with placebo for the treatment of tardive dyskinesia (TD) in adult participants.
- Trial name
- NCT07365462
- Testing
- NBI-1065890
- Where
- 18 sites in United States
- Volunteers
- 100 people
- Sponsor
- Neurocrine Biosciences
Metastatic Breast Cancer With HER2 Positive
SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive Breast Cancer
The goal of this clinical trial is to learn if SHR-A1811 combine with Pyrotinib is safe and tolerable for patients with HER2 positive breast cancer. It will also learn about the anti-tumor efficacy of this combination therapy.
- Trial name
- NCT07132242
- Testing
- SHR-A1811 4.0mg/kg, Pyrotinib 240mg, SHR-A1811 4.8mg/kg
- Volunteers
- 84 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Hidradenitis Suppurativa (HS)
The Safety and Efficacy of Roflumilast Foam in HS
This study investigates the efficacy of topical roflumilast foam in patients with HS.
- Trial name
- NCT07263230
- Testing
- Roflumilast 0.3% topical foam
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Beth Israel Deaconess Medical Center
Obsessive-compulsive Disorder
Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe OCD
Obsessive-compulsive disorder (OCD) is a neuropsychiatric disorder characterized by recurrent distressing thoughts and substantial anxiety, accompanied by repetitive behaviors or mental rituals.
- Trial name
- NCT04882839
- Testing
- psychotherapy assisted psilocybin
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Beersheva Mental Health Center
Diabetes Mellitus, Type 2
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide.
- Trial name
- NCT07415954
- Testing
- NNC0662-0419, Semaglutide
- Where
- 63 sites in United States, Croatia and 8 more
- Volunteers
- 270 people
- Sponsor
- Novo Nordisk A/S
Uncontrolled Hypertension
Netrod-Pilot Study of Renal Denervation With NetrodTM Sixelectrode Radiofrequency RDN System
This single-arm, non-randomized, open-label investigation aims to collect safety and efficacy data of the CE-Marked Netrod™ RDN System in treating European patients with primary hypertension in the absence of anti-hypertensive…
- Trial name
- NCT07061054
- Testing
- Netrod™ six-electrode radiofrequency renal denervation system
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Shanghai Golden Leaf MedTec Co. Ltd
Efficacy and Safety
A Study on the Short-course Treatment Regimen Containing Pretomanid for Drug-resistant Tuberculosis
Rifampicin-resistant tuberculosis (RR-TB) is characterized by a long treatment course, high incidence of adverse reactions, low cure rate and high recurrence rate.
- Trial name
- BPaLM (NCT07126639)
- Testing
- bedaquiline, Pretomanid (Pa), linezolid
- Volunteers
- 200 people
- Sponsor
- Wuhan Pulmonary Hospital
Acute Myeloid Leukemia
Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML
The goal of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of RVU120 when administered in combination with venetoclax to adult patients with acute myeloid leukemia…
- Trial name
- RIVER-81 (NCT06191263)
- Testing
- RVU120, Venetoclax
- Where
- 37 sites in France, Italy and 2 more
- Volunteers
- 98 people
- Sponsor
- Ryvu Therapeutics SA
End Stage Renal Disease on Dialysis, Adult
A Study to Test the Safety of the Study Drug Fosmanogepix and How the Body Handles It in Adults With Severe Kidney Failure on Dialysis
This study will evaluate how fosmanogepix is processed by the body (pharmacokinetics, PK) in participants with kidney failure (end-stage renal disease (ESRD) requiring intermittent hemodialysis (IHD) compared with participants…
- Trial name
- NCT07916181
- Testing
- Intravenous fosmanogepix
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Basilea Pharmaceutica
Atopic Dermatitis
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis.
- Trial name
- NCT06807281
- Testing
- Abrocitinib
- Where
- 40 sites in United States, China and 5 more
- Volunteers
- 450 people
- Sponsor
- Pfizer
Fibromyalgia, Pregabalin
The Efficacy and Safety of Pregabalin and Crisugabalin in Patients With Fibromyalgia
Fibromyalgia (FM) is a chronic pain syndrome characterized by widespread pain, fatigue, and emotional disorders. Its onset is related to factors such as central sensitization and imbalance of neurotransmitters.
- Conditions
- Fibromyalgia, Pregabalin, Pain
- Trial name
- NCT07196657
- Testing
- Pregabalin, Crisugabalin
- Where
- China
- Volunteers
- 1,116 people
- Sponsor
- Beijing Tiantan Hospital
Fibromyalgia, Pregabalin
The Efficacy and Safety of Pregabalin Combined With Desvenlafaxine in Patients With Fibromyalgia
Fibromyalgia (FM) is a chronic pain syndrome characterized by widespread pain, fatigue, and emotional disorders. Its onset is related to factors such as central sensitization and imbalance of neurotransmitters.
- Conditions
- Fibromyalgia, Pregabalin, Pain
- Trial name
- NCT07171320
- Testing
- Pregabalin, Pregabalin with desvenlafaxine
- Where
- China
- Volunteers
- 384 people
- Sponsor
- Beijing Tiantan Hospital
Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of firmonertinib at a dose level of 240 mg QD compared to investigator's choice of osimertinib (80 mg QD) or afatinib (40 mg QD) in…
- Conditions
- Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing
- Trial name
- NCT07185997
- Testing
- Firmonertinib, EGFR-TKI inhibitor based on investigator's choice
- Where
- 141 sites in United States, Australia and 15 more
- Volunteers
- 480 people
- Sponsor
- ArriVent BioPharma, Inc.